AU2001249684A1 - Nasal administration of agents for the treatment of gastroparesis - Google Patents

Nasal administration of agents for the treatment of gastroparesis

Info

Publication number
AU2001249684A1
AU2001249684A1 AU2001249684A AU4968401A AU2001249684A1 AU 2001249684 A1 AU2001249684 A1 AU 2001249684A1 AU 2001249684 A AU2001249684 A AU 2001249684A AU 4968401 A AU4968401 A AU 4968401A AU 2001249684 A1 AU2001249684 A1 AU 2001249684A1
Authority
AU
Australia
Prior art keywords
gastroparesis
treatment
agents
nasal administration
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249684A
Other languages
English (en)
Inventor
Laura S. Lehman
Ruth Oliver
Michael Petrone
Anastassios D. Retzios
David Tierney
Carol B. Trapnell
David Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire US Inc
Mallinckrodt ARD Inc
Original Assignee
Questcor Pharmaceuticals Inc
Shire US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Questcor Pharmaceuticals Inc, Shire US Inc filed Critical Questcor Pharmaceuticals Inc
Publication of AU2001249684A1 publication Critical patent/AU2001249684A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001249684A 2000-03-30 2001-03-30 Nasal administration of agents for the treatment of gastroparesis Abandoned AU2001249684A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19318100P 2000-03-30 2000-03-30
US60193181 2000-03-30
PCT/US2001/010356 WO2001074350A1 (en) 2000-03-30 2001-03-30 Nasal administration of agents for the treatment of gastroparesis

Publications (1)

Publication Number Publication Date
AU2001249684A1 true AU2001249684A1 (en) 2001-10-15

Family

ID=22712552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249684A Abandoned AU2001249684A1 (en) 2000-03-30 2001-03-30 Nasal administration of agents for the treatment of gastroparesis

Country Status (12)

Country Link
US (2) US6770262B2 (de)
EP (1) EP1274414B1 (de)
KR (1) KR20030004361A (de)
AT (1) ATE466569T1 (de)
AU (1) AU2001249684A1 (de)
CA (1) CA2403994C (de)
CY (1) CY1111396T1 (de)
DE (1) DE60142037D1 (de)
DK (1) DK1274414T3 (de)
ES (1) ES2346290T3 (de)
PT (1) PT1274414E (de)
WO (1) WO2001074350A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
US6979562B2 (en) * 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
CA2550811C (en) * 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
CA2780485C (en) * 2008-12-22 2017-12-12 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
SG192838A1 (en) 2011-03-23 2013-09-30 Raqualia Pharma Inc A 5-ht4 receptor agonist as a prokinetic agent
CA2846340A1 (en) * 2011-08-25 2013-02-28 Matthew J. D'onofrio Treatment of symptoms associated with female gastroparesis
KR102526521B1 (ko) * 2014-05-16 2023-04-27 라퀄리아 파마 인코포레이티드 위부전마비용 5-ht4 수용체 작용제
CN104606136A (zh) * 2015-01-06 2015-05-13 中国人民解放军军事医学科学院毒物药物研究所 甲氧氯普胺鼻腔喷雾剂、其制备方法及用途
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
EP3681573A4 (de) * 2017-09-11 2021-08-04 Evoke Pharma, Inc. Verfahren zur dosierung von intranasalem metoclopramid
US11786512B2 (en) 2019-09-23 2023-10-17 Slayback Pharma Llc Stable pharmaceutical compositions of dihydroergotamine mesylate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624965A (en) 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4729997A (en) 1985-10-15 1988-03-08 Nastech Pharmaceutical Co., Inc. Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same
FR2640139A1 (fr) 1988-12-14 1990-06-15 Delagrange Laboratoires Application de benzamides substitues comme gastromoteurs
CH681690A5 (en) 1990-09-28 1993-05-14 Kali Chemie Pharma Gmbh New metoclopramide salt compsns. with no additives
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5760086A (en) 1996-03-14 1998-06-02 Ribogene, Inc. Nasal administration of agents for treatment of delayed onset emesis

Also Published As

Publication number Publication date
KR20030004361A (ko) 2003-01-14
ATE466569T1 (de) 2010-05-15
CA2403994A1 (en) 2001-10-11
EP1274414B1 (de) 2010-05-05
PT1274414E (pt) 2010-08-10
US6770262B2 (en) 2004-08-03
US20020065321A1 (en) 2002-05-30
DK1274414T3 (da) 2010-08-30
EP1274414A1 (de) 2003-01-15
CY1111396T1 (el) 2015-08-05
EP1274414A4 (de) 2007-08-22
CA2403994C (en) 2011-08-23
US20030059374A1 (en) 2003-03-27
WO2001074350A1 (en) 2001-10-11
ES2346290T3 (es) 2010-10-14
DE60142037D1 (de) 2010-06-17

Similar Documents

Publication Publication Date Title
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
MXPA04009163A (es) Nuevos compuestos.
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
TW200510375A (en) New compounds
EP0923376A4 (de) Behandlung von asthma und atemwegerkrankungen
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
SE0100569D0 (sv) New compounds
DE59800935D1 (en) Immuntolerante prothrombinkomplex-präparation
WO2002096362A3 (en) Method for treating fibrotic diseases or other indications vi
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
EP1019047A4 (de) Antithrombotische mittel
GB9907571D0 (en) Compounds
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
EP0891186A4 (de) Nasale verabreichung von substanzen zur behandlung der tardiven emesis
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
SE0004827D0 (sv) Therapeutic compounds
AU2002254930A1 (en) Novel medicament compositions based on anticholinergic agents and endothelin antagonists
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
HUT75939A (en) Intranasal composition containing active ingredient having antimigraine effect and chitosan
AU2002211217A1 (en) Method of treating stroke
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects